Health Yuan announced that it recently received the “Drug Registration Certificate” for mapaxavir capsules approved and issued by the State Drug Administration. This drug is an innovative new anti-influenza drug and is suitable for the treatment of specific patients. It only needs to be taken once during the entire course of the disease. It is effective against influenza A and B, has outstanding curative effects for young patients, has a low risk of drug resistance, and has safety advantages. As of the date of disclosure of the announcement, the drug has invested a total of about 2030,0361 million yuan in research and development. In 2024, domestic anti-influenza drug terminal sales will be about 4.7 billion yuan. Pharmaceutical production and sales are affected by various factors, and there is uncertainty.

Health Yuan announced that it recently received the “Drug Registration Certificate” for mapaxavir capsules approved and issued by the State Drug Administration. This drug is an innovative new anti-influenza drug and is suitable for the treatment of specific patients. It only needs to be taken once during the entire course of the disease. It is effective against influenza A and B, has outstanding curative effects for young patients, has a low risk of drug resistance, and has safety advantages. As of the date of disclosure of the announcement, the drug has invested a total of about 2030,0361 million yuan in research and development. In 2024, domestic anti-influenza drug terminal sales will be about 4.7 billion yuan. Pharmaceutical production and sales are affected by various factors, and there is uncertainty.